



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Julius Remenar et al.

Serial No.: 10/601,092

Group No.: 1614

Filed: 06/20/2003

Examiner:

For: PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION

Attorney Docket Number: TPIP017

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Applicants submit these documents in compliance with the duty of disclosure as defined in 37 CFR §1.56, §1.97, and §1.98. The Examiner is requested to make these citations of official record in the present application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

The Information Disclosure Statement transmitted herewith is being filed *after* three months of the filing date of this national application but *before* the mailing date of the first Office action on the merits.

10/28/2004 HAL111 00000042 10601092

01 FC:1806 180.00 DA

A copy of a PCT International Search Report from a counterpart application is enclosed.

Legible copies of all items listed in Form PTO-1449 accompany this information disclosure

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify that under 37 CFR §1.8(a) that this correspondence is being deposited on October 22, 2004 with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kristin Kaberry
Kristin Kaberry

statement. Cumulative patents or publications identified in the attached PCT Search Report are not enclosed.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c)(2). The Commissioner is hereby authorized to charge this fee of \$180.00 to Deposit Account No. 502626.


The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

Respectfully submitted,

Date Oct 21, 2004

By:


Paul Burgess
Registration No. 53,852
Transform Pharmaceuticals, Inc.
29 Hartwell Avenue
Lexington, MA 02421
Tel. #(781) 863-7816
Fax #(781) 863-7208



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/601,092
Filing Date	06/20/2003
First Named Inventor	Julius Remenar
Art Unit	1614
Examiner Name	
Attorney Docket Number	TP1P017

U. S. PATENT DOCUMENTS


[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/601,092

Filing Date 06/20/2003

First Named Inventor Julius Remenar

Art Unit 1614

Examiner Name

Attorney Docket Number TPIP017

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Database, WPI, Section Ch, Week 197936, Derwent Publications Ltd., London, GB, Class B02, AN 1979-65538B XP002282989 & JP 54 095589 A (Sumitomo) 1979 abstract	
		Fung et al., Solvent Effects on Comparative Dissolution of Pharmaceutical Solvates, Chem. Farm. Bull., 22(2), pgs. 454-458 (1974)	
		Rubino et al., Influence of solvent composition on the solubilities and solid-state properties of the sodium salts of some drugs", Int. J. of Pharma., 65, pgs. 141-145 (1990)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.